<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01064024</url>
  </required_header>
  <id_info>
    <org_study_id>AM-PHN-001</org_study_id>
    <nct_id>NCT01064024</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg vs. Placebo</brief_title>
  <official_title>A Double Blind, Randomized, Parallel Controlled Study to Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg vs. Placebo as a Urinary Analgesic for Short Term Treatment in Female Subjects Suffering From Pain or Burning When Passing Urine Associated With Uncomplicated Urinary Tract Infections (uUTI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amneal Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oxford Pharmaceutical Resources, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sristek Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biostudy Solutions, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Amneal Pharmaceuticals, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of Phenazopyridine Hydrochloride Tablets,&#xD;
      USP 200 mg as a short term analgesic treatment for the primary symptoms of pain or burning&#xD;
      when passing urine associated with uncomplicated urinary tract infections (uUTI)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of subjects in each treatment group who demonstrate reduction in pain or burning when passing urine.</measure>
    <time_frame>24 hrs after first dose and 48 hrs after second dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">233</enrollment>
  <condition>Pain</condition>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Phenazopyridine Hydrochloride Tablets, USP 200 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo to the phenazopyridine hydrochloride tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenazopyridine Hydrochloride</intervention_name>
    <description>Tablets, 200 mg, every 8 hours for 48 hours.</description>
    <arm_group_label>Phenazopyridine Hydrochloride Tablets, USP 200 mg</arm_group_label>
    <other_name>Pyridium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, every 8 hours for 48 hours</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of uncomplicated urinary tract infection (uUTI)&#xD;
&#xD;
          -  Must have one of the following uUTI diagnosis&#xD;
&#xD;
          -  Cystitis&#xD;
&#xD;
          -  Urethritis&#xD;
&#xD;
          -  A Positive urine dipstick test showing nitrate or leukocyte esterase (LE)&#xD;
&#xD;
          -  Negative pregnancy test (if applicable)&#xD;
&#xD;
          -  Must have one or both of the following symptoms of&#xD;
&#xD;
          -  pain upon urination&#xD;
&#xD;
          -  burning upon urination&#xD;
&#xD;
          -  In addition, one of the following symptoms&#xD;
&#xD;
          -  Not being able to empty bladder completely&#xD;
&#xD;
          -  Pain or discomfort in lower abdomen, or pelvic areas&#xD;
&#xD;
          -  Frequent urge to urinate&#xD;
&#xD;
          -  Blood in urine&#xD;
&#xD;
          -  None&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any diagnosis of a urinary tract or kidney disorder that is not a uUTI&#xD;
&#xD;
          -  A diagnosis of Pyelonephritis (kidney infections when lower uUTI spreads to the upper&#xD;
             tract)&#xD;
&#xD;
          -  Women with a history of prior use of phenazopyridine hydrochloride&#xD;
&#xD;
          -  Women who have taken any systemic anti-infectives within seven days of study&#xD;
             participation&#xD;
&#xD;
          -  Women with a history of G-6-PD deficiency or hemolytic anemia&#xD;
&#xD;
          -  Women who have a known history of anatomical genitourinary (GU) anomalies or GU&#xD;
             surgery within the past 6 months&#xD;
&#xD;
          -  Women of child bearing age who do not consent to a pregnancy test&#xD;
&#xD;
          -  Women who are lactating&#xD;
&#xD;
          -  Chronic infection of the urinary tract requiring an intravenous pyelogram (IVP),&#xD;
             ultrasound or cystoscopy&#xD;
&#xD;
          -  Subjects with clinically significant abnormal results or finding on the screening&#xD;
             physical examination, laboratory tests, vital signs or ECG.&#xD;
&#xD;
          -  Subjects unable to comprehend the language of the informed consent and the self&#xD;
             evaluation scales.&#xD;
&#xD;
          -  Subjects with serious acute illness (e.g. pneumonia) or an untreated or unstable&#xD;
             medical illness that would likely interfere with assessments of uUTI&#xD;
&#xD;
          -  Subjects who have received an investigational medication as part of a drug trial 3&#xD;
             months prior to the baseline study visit&#xD;
&#xD;
          -  Subjects with a history of severe drug allergy or hypersensitivity&#xD;
&#xD;
          -  Subjects with a known sensitivity to Phenazopyridine, Hyoscyamine, Butabarbital and&#xD;
             antibiotics.&#xD;
&#xD;
          -  Employees of the investigator or the institution who have direct involvement in the&#xD;
             trial or other trials under the direction of the investigator or their associates.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oxford Pharmaceutical Resources, Inc.</name>
      <address>
        <city>Totowa</city>
        <state>New Jersey</state>
        <zip>07512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>February 4, 2010</study_first_submitted>
  <study_first_submitted_qc>February 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2010</study_first_posted>
  <disposition_first_submitted>January 24, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>January 24, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 29, 2013</disposition_first_posted>
  <last_update_submitted>January 24, 2013</last_update_submitted>
  <last_update_submitted_qc>January 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uUTI</keyword>
  <keyword>Pain or burning associated with Uncomplicated Urinary Tract Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

